跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
anti-BCMA CAR T-cell therapy
首页
药物
anti-BCMA CAR T-cell therapy
anti-BCMA CAR T-cell therapy
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
Preparation method and application of BCMA-targeting tumor antigen receptor modified T cell
申请人: FAN KEXING
优先权: 2020
CN
CHIMERIC ANTIGEN RECEPTORS SPECIFIC TO B-CELL MATURE ANTIGEN (BCMA) AND/OR TRANSMEMBRANE ACTIVATOR AND CAML INTERACTOR (TACI)
申请人: ELPIS BIOPHARMACEUTICALS
优先权: 2022
CN
EP
US
WO
4 件公开
ANTI-BCMA CAR T CELL COMPOSITIONS
申请人: BLUEBIRD BIO INC
优先权: 2016
CN
EP
US
WO
7 件公开
METHODS COMPRISING ONCOLYTIC VIRUSES EXPRESSING BCMAT AND BCMA-TARGETED THERAPIES
申请人: HOPE CITY
优先权: 2024
WO
Combination therapy of ATRA or other retinoic acid with immunotherapeutic agents that bind to BCMA
申请人: UNIV WUERZBURG J MAXIMILIANS
优先权: 2020
CN
NOVEL DUAL SPLIT CAR-T CELLS FOR THE TREATMENT OF CD38-POSITIVE HEMATOLOGICAL MALIGNANCIES
申请人: INST NAT SANTE RECH MED
优先权: 2022
EP
WO
2 件公开
METHOD TO GENERATE IMPROVING CAR-T CELLS
申请人: INST NAT SANTE RECH MED
优先权: 2022
EP
US
WO
3 件公开
METHODS FOR TREATING MULTIPLE MYELOMA WITH CAR-T CELLS AND BISPECIFIC ANTIBODIES
申请人: JANSSEN BIOTECH INC
优先权: 2024
US
WO
2 件公开
药物
反馈